Lonza signs manufacturing deal with US biotech firm

Lonza says it has entered into a process transfer and manufacturing agreement with Celladon Corp. (San Diego, CA), a privately held biotechnology company focused on the discovery and development of treatments for cardiovascular diseases. Lonza, under the terms of the agreement, will manufacture cGMP-grade Mydicar, Celladon’s product candidate for the treatment of advanced heart failure, for use in future clinical trials. In the event Celladon intends to commence commercial scale manufacture of Mydicar, Celladon and Lonza have agreed to negotiate a...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers